Mergers & AcquisitionsBy The Online Investor Staff, updated Wed., Feb. 26, 6:46 PM
|This Slide: #60 of 100|
Slide #60. Roche — Promedior, Inc.
Promedior, Inc. today announced the successful completion of its previously announced sale to Roche (SIX: RO, ROG; OTCQX: RHHBY). With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Under the terms of the merger agreement, Roche made an upfront cash payment of USD 390 million, with additional contingent payments of up to USD 1 billion to be made based on the achievement of certain predetermined development, regulatory and commercial milestones.